미국 - 영어 - NLM (National Library of Medicine)

avera mckennan hospital - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - stribild® is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies/ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of stribild [see clinical studies (14)] . coadministration of stribild is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of stribild and possible resistance) are listed in table 1 [see drug interactions (7.5) and clinical pharmacology (12.3)]. pregnancy exposure registry there is a pregnancy exp

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - elvitegravir 150mg;  ;  ;  ;   - film coated tablet - 150 mg - active: elvitegravir 150mg         excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f91203 sodium laurilsulfate - indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults and adolescents when co-administered with a ritonavir-boosted protease inhibitor and other antiretroviral therapy.

캐나다 - 영어 - Health Canada

gilead sciences canada inc - elvitegravir - tablet - 150mg - elvitegravir 150mg - hiv integrase inhibitors

이스라엘 - 영어 - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat - stribild is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with hiv 1 without known mutations associated with resistance to any of the three antiretroviral agents in stribild.תוספת התוויה: 2/7/2019addition of new info to posology section: precaution in pregnant women

이스라엘 - 영어 - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat - stribild is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with hiv 1 without known mutations associated with resistance to any of the three antiretroviral agents in stribild.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg;  ;  ;  ; elvitegravir 150mg;  ;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: cobicistat 150mg       elvitegravir 150mg     emtricitabine 200mg         tenofovir disoproxil fumarate 300mg       excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green sodium laurilsulfate - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-naive adults. stribild is also indicated in certain virologically suppressed (hiv1 rna stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - cobicistat 150mg (as a blend with silicon dioxide);  ;  ;  ; elvitegravir 150mg;  ;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg);   - tablet - active: cobicistat 150mg (as a blend with silicon dioxide)       elvitegravir 150mg     emtricitabine 200mg         tenofovir alafenamide 10mg (as tenofovir alafenamide fumarate 11.2mg)   excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f110095 sodium laurilsulfate - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment-na?ve; or virologically suppressed (hiv-1 rna genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

싱가포르 - 영어 - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - darunavir ethanolate 162.62 mg eqv darunavir - tablet, film coated - 150mg - darunavir ethanolate 162.62 mg eqv darunavir 150mg

유럽 연합 - 영어 - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infections - antivirals for systemic use - vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (hiv-1) infection in adults who are infected with hiv-1 without known mutations associated with resistance to elvitegravir.

유럽 연합 - 영어 - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infections - antivirals for systemic use, - genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.,